Pregnancy Cat

Dacomitinib can cause fetal harm when administered to a pregnant woman. There is no information regarding the presence of dacomitinib or its metabolites in human milk or their effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants from Dacomitinib, advise women not to breastfeed during treatment with Dacomitinib and for at least 17 days after the last dose.

Precautions

Interstitial Lung Disease (ILD): Permanently discontinue Dacomitinib if ILD is confirmedDiarrhea: Withhold and reduce the dose of DACOMITINIB based on the severityDermatologic Adverse Reactions: Withhold and reduce the dose of DACOMITINIB based on the severityEmbryo-Fetal Toxicity: Dacomitinib can cause fetal harm. Advise females of reproductive potential to use effective contraception.

Overdose Effects

n/a

Drug Classes

Cytotoxic Chemotherapy

Storage Conditions

Do not store above 30⁰C. Keep away from light and out of the reach of children.

Composition

n/a

Mode Of Action

Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. Dacomitinib demonstrated dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in mice bearing subcutaneously implanted human tumor xenografts driven by HER family targets including mutated EGFR. Dacomitinib also exhibited antitumor activity in orally-dosed mice bearing intracranial human tumor xenografts driven by EGFR amplifications.

Reconstitution

n/a